Research theme for competitive and other funds (3)：
2013 - 2016 Where and how are mature platelets produced?
1998 - 2002 白血病の微少残存病変の定量
1998 - 2002 The quantitation of minimal residual disease in acute leukemia
Papers (88)：
Yuichi Horigome, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Hiroshi Handa, Yasushi Hiramatsu, Taiga Kuroi, Kazuki Tanimoto, Kosei Matsue, Masahiro Abe, et al. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan. Annals of hematology. 2023
Shugo Kowata, Yuki Seki, Yasuhiko Tsukushi, Tsuyoshi Sato, Kazuya Asano, Takahiro Maeta, Akiko Yashima-Abo, Ryosei Sasaki, Yoshiaki Okano, Tatsuo Oyake, et al. Association of CD8 + T cells expressing nivolumab-free PD-1 with clinical status in a patient with relapsed refractory classical Hodgkin lymphoma. International journal of hematology. 2023
Ryosuke Kinoshita, Mariko Ishibashi, Hiroshi Handa, Makoto Sasaki, Yoichi Imai, Norina Tanaka, Shigeki Ito, Mika Sunakawa-Kii, Yuta Kaito, Toshio Asayama, et al. The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma. Experimental hematology. 2023
Yasushi Onishi, Eijiro Furukawa, Mayumi Kamata, Masahiko Fukatsu, Yoshihiro Kameoka, Shunsuke Hatta, Hiroyuki Hamada, Tatsuo Oyake, Tatsuyuki Kai, Masumi Sukegawa, et al. Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL. International Journal of Hematology. 2023. 117. 5. 738-747
Yoshitaka Imaizumi, Masako Iwanaga, Kisato Nosaka, Kenji Ishitsuka, Kenichi Ishizawa, Shigeki Ito, Masahiro Amano, Takashi Ishida, Naokuni Uike, Atae Utsunomiya, et al. Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study. International Journal of Hematology. 2022. 117. 2. 206-215
Mariko Ishibashi, Ryosuke Kinoshita, Koiti Inokuchi, Hiroshi Handa, Makoto Sasaki, Norio Komatsu, Yoichi Imai, Norina Hiroike, Junji Tanaka, Sakae Tanosaki, et al. Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression. BLOOD. 2019. 134
Akio Saito, Atsushi Isoda, Takeshi Odajima, Mitsuhiro Itagaki, Go Yamamoto, Shotaro Hagiwara, Tatsuharu Ohno, Ayumi Fujimoto, Naohiro Sekiguchi, Kazutaka Sunami, et al. A New Prognostic Index for Waldenstrom Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma. BLOOD. 2018. 132
